Key clinical point: The 12-week injection cycle of Onabotulinumtoxin A (OnabotA) may need to be reconsidered.
Major finding: The study of 98 patients and 471 treatment cycles found that 43 patients experienced one or more wearing-off-effect (WOE) events (worsening headaches and neck pain). Of those patients, 24 reported 1 WOE event and 19 patients reported 2 or more WOEs. Almost 32% of patients used abortive therapy to manage their WOEs.
Study details: This was a retrospective review of patients with worsening headache variables and neck pain who received OnabotA for their chronic migraine in treatment cycles.
Disclosures: Dr. Khan received honorarium for Depomed, Inc. and Promius Pharma while conducting the study.
Citation: Khan FA, et al. Headache. 2019 Nov 22. doi: 10.1111/head.13713. [Epub ahead of print].